Skip Ribbon Commands
Skip to main content
Dr Than Hein

Dr Hein Than

MBBS, MRCP(UK), MMed(Int Med), FRCPath(UK), FAMS

Senior Consultant

Singapore General Hospital

Specialty: Haematology

Clinical Interest: Acute Leukemia, Myeloproliferative Neoplasm, Haematopoietic Stem Cell & Cellular Therapy

Conditions Treated by this Doctor:
Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukaemia, Aplastic Anaemia, Chronic lymphocytic leukemia, Chronic Myeloid Leukaemia, Haematopoietic Stem Cell Transplant, Lymphoma, Multiple Myeloma, Myelodysplastic Neoplasm (MDS), Myelofibrosis, Myeloproliferative Neoplasms.

Clinical Appointments

  • Senior Consultant SingHealth Duke-NUS Blood Cancer Centre
  • Senior Consultant Haematology Singapore General HospitalSingapore General Hospital
  • Senior Consultant National Cancer Centre SingaporeNational Cancer Centre Singapore

Academic Appointments

  • Clinical Lecturer, Yong Loo Lin School of Medicine, National University of Singapore
  • Clinical Assistant Professor, Duke-NUS Medical School Singapore


Dr Than Hein is a Senior Consultant with the Department of Haematology at Singapore General Hospital, and a Clinical Assistant Professor at the Duke-NUS Medical School Singapore. His sub-specialty interest is in haematology-oncology, particularly myeloproliferative neoplasm, acute leukaemia and haematopoietic stem cell transplantation. He completed his basic specialist training in Internal Medicine in 2011 and advanced specialist training in Haematology in 2014. He is an accredited specialist fellow of the Royal College of Pathologists (UK) and the Academy of Medicine (Singapore). 
His research interest is to understand the genetic interplay between haematopoietic stem cells and bone marrow environment to optimize targeted treatment of leukaemia and other blood/ bone marrow cancers. His research work on genomics in leukaemia from 2016 to 2018 was supported by SingHealth Health Manpower Development Plan (HMDP) Award and National Medical Research Council, Singapore (NMRC) Research Training Fellowship. He is a winner of Nurturing Clinician Scientist Scheme (NCSS) Award from SingHealth Duke-NUS Medicine Academic Medicine Programme.


  • FRCPath (UK) (RCPath, United Kingdom) 2016 
  • FAMS (Singapore) 2015
  • MMed (Int Med) (NUS, Singapore) 2011
  • MRCP (UK) (RCP, United Kingdom) 2010

Professional Appointments and Committee Memberships

  • Head, Haematology Molecular Laboratory, Singapore General Hospital
  • Lead, Diagnostics, SingHealth Duke-NUS Blood Cancer Centre (SDBCC) Executive Committee
  • Lead, Chronic Myeloid Leukaemia, SingHealth Duke-NUS Blood Cancer Centre (SDBCC) Executive Committee
  • Clinical Assistant Professor, Duke-NUS Medical School Singapore
  • Clinical Lecturer, Yong Loo Lin School of Medicine, National University of Singapore
  • Clinical Core Faculty Member, National Haematology Senior Residency Training Programme


  • SingHealth Publish! Award (2021)
  • Faculty Appreciation Award, SingHealth Residency Programme (2020/2021)
  • Outstanding Faculty Award, SingHealth Residency Programme (2019/2020)
  • Khoo Pilot Research Award (Collaborative), SingHealth Duke-NUS Medicine Academic Medicine Programme (2019)
  • Nurturing Clinician Scientist Scheme (NCSS) Award, SingHealth Duke-NUS Medicine Academic Medicine Programme (2018)
  • 10-Years Long Service Award, Singapore General Hospital (2018)
  • Special Recognition Award as a Role Model to the Medicine Graduating Class of 2018, National University of Singapore (2018)
  • National Medical Research Council Singapore, Research Training Fellowship (2016)
  • SingHealth Health Manpower Development Plan (HMDP) Award (2015)
  • Singapore Health Quality Service Award (STAR category) (2015)
  • Singapore Health Quality Service Award (2014)
  • Service with a Heart Award (2008, 2014)

Research Interests

  • Leukaemia and myeloid neoplasms
  • Genomics in leukaemia
  • Haematopoietic stem cell and regeneration


Selected Publications

  1. Krishnan V, Schmidt F, Nawaz Z, Venkatesh PN, Lee KL et al. A single-cell atlas identifies pre-treatment features of primary imatinib resistance in chronic myeloid leukemia. Blood. 2023 Mar. Online ahead of print. PMID: 36857629
  2. Yan D, Franzini A, Pomicter AD, Halverson BJ, Antelope O, Mason CC, et al. SIRT 5 is a druggable metabolic vulnerability in acute myeloid leukemia. Blood cancer Discov. 2021 May;2(3):266–87.
  3. Pwint K-SW, Chen Y, Diong CP, Goh Y-T, Grant D, Ho A, et al. Mobilization kinetics of peripheral blood stem cells with rescue plerixafor - real-world experience from a single center. Vol. 61, Leukemia & lymphoma. United States; 2020. p. 1740–3.
  4. Sinnakannu JR, Lee KL, Cheng S, Li J, Yu M, Tan SP, et al. SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia. Leukemia. 2020 Jul;34(7):1787–98.
  5. Than H, Pomicter AD, Yan D, Beaver LP, Eiring AM, Heaton WL, et al. Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells. Vol. 34, Leukemia. 2020. p. 1679–83.
  6. Lam Yi H, Than H, Sng C, Cheong MA, Chuah C, Xiang W. Lysosome Inhibition by Mefloquine Preferentially Enhances the Cytotoxic Effects of Tyrosine Kinase Inhibitors in Blast Phase Chronic Myeloid Leukemia. Transl Oncol. 2019 Sep;12(9):1221–8.
  7. Franzini A, Pomicter AD, Yan D, Khorashad JS, Tantravahi SK, Than H, et al. The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations. Blood Adv. 2019 Oct;3(20):2949–61.
  8. Eide CA, Zabriskie MS, Savage Stevens SL, Antelope O, Vellore NA, Than H, et al. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell. 2019 Oct;36(4):431-443.e5.
  9. Zhang H, Wilmot B, Bottomly D, Dao K-HT, Stevens E, Eide CA, et al. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood. 2019 Sep;134(11):867–79.
  10. Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina A V, Ahmann JM, et al. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis. Clin cancer Res an Off J Am Assoc Cancer Res. 2019 Apr;25(7):2323–35.
  11. Than H, Lye WK, Sng C, Allen JCJ, Ong ST, Chuah C. BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients. Vol. 60, Leukemia & lymphoma. United States; 2019. p. 234–7.
  12. Than H, Qiao Y, Huang X, Yan D, Khorashad JS, Pomicter AD, et al. Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective. Leukemia. 2018 Sep;32(9):2049–54.
  13. Ong SY, Chin YA, Than H, Tan CW, Yap ES, Wong WH, et al. Rivaroxaban for heparin-induced thrombocytopenia: adding to the evidence. Vol. 96, Annals of hematology. Germany; 2017. p. 525–7.
  14. Than H, Loh JBE, Sum CLL, Ng HJ. Clinical utility of anti-Xa monitoring and differential sensitivity of prothrombin time assays: an illustrated case report. Vol. 68, Journal of clinical pathology. England; 2015. p. 318–9.
  15. Xiang W, Cheong JK, Ang SH, Teo B, Xu P, Asari K, et al. Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration. Oncotarget. 2015 Oct;6(32):33769–80.
  16. Ng KP, Hillmer AM, Chuah CTH, Juan WC, Ko TK, Teo ASM, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012 Mar;18(4):521–8.

Research Trials